Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications [6]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 9, 2006, Pages 2083-2085

  Chapman, William C ^a   Lockstadt, H ^b   Singla, N ^c   Kafie, F E ^d   Lawson, J H ^e  

^a WASHINGTON UNIVERSITY   (United States)

^b Bluegrass Orthopedics ^*  (United States)

^c HUNTINGTON MEMORIAL HOSPITAL   (United States)

^d Baptist Hospital Pensacola   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN SPONGE; GELFOAM; RECOMBINANT HUMAN THROMBIN; RHTHROMBIN; THROMBIN; UNCLASSIFIED DRUG;

ARTERY BYPASS; BLEEDING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMOSTASIS; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INSOMNIA; LETTER; LIVER RESECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE SURGERY; THROMBOSIS; VASCULAR ACCESS; VASCULAR DISEASE; VOMITING; WOUND INFECTION;

ANTIBODY SPECIFICITY; DOUBLE-BLIND METHOD; GELATIN SPONGE, ABSORBABLE; HEMOSTASIS, SURGICAL; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS; THROMBIN;

EID: 33747160749     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02067.x     Document Type: Letter

References (12)

1. Schoenecker JG, Johnson RK, Fields RC, Lesher AP, Domzalski T, Baig K, Lawson JH, Parker W. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003; 197: 580-90.
2. Wai Y, Tsui V, Peng Z, Richardson R, Oreopoulos D, Tarlo SM. Anaphylaxis from topical bovine thrombin (Thrombostat®) during haemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 2003; 33: 1730-4.
3. Sands JJ, Nudo SA, Ashford RG, Moore KD, Ortel TL. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000; 35: 796-801.
4. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
5. Streiff M, Ness P. Acquired FV Inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42: 18-26.
6. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004; 18: 349-51.
7. Lawson JH, Lynn KA, Vanmatre RM, Domzalski T, Klemp KF, Ortel TL, Niklason LE, Parker W. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005; 78: 1037-8.
8. Luban NL. The spectrum of safety: A review of the safety of current hemophilia products. Semin Hematol 2003; 40: 10-5.
9. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, Ritchie B, Siegel J, Simmonds P, Stanley S, Tapper ML, von Depka M. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367: 252-61.
10. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1-16.
11. Winterbottom N, Kuo JM, Nguyen K, Reich CJ, Trent KJ, Rondinone JF, Shargill NS. Antigenic responses to bovine thrombin exposure during surgery: A prospective study of 309 patients. J Appl Res Clin Exp Ther 2002; 2: 1-12.
12. Wei LJ, Lin DJ, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84: 1065-73.